公开(公告)号：US20210161111A1

公开(公告)日：2021-06-03

申请号：US16651200

申请日：2018-09-20

Applicant: GREEN CROSS CORPORATION ,  MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： So Ra KIM ,  Myung Eun JUNG ,  Min Jung KIM ,  Seung Hyun JO ,  Sung Ho HWANG ,  Hee Chun KWAK ,  Su Min LEE ,  Hyun Ja NAM

IPC: A01K67/027 ,  C12N15/113 ,  C12N9/22

Abstract: The present invention relates to a factor VIII or factor IX gene knockout rabbit, a method for preparing the same and a use thereof and, more particularly, to a transgenic rabbit whose factor VIII or factor IX gene has been knocked out through the CRISPR/Cas9 system, a method for preparing the same and a use thereof. According to the present invention, in the transgenic rabbit, whose factor VIII and/or factor IX gene has been knocked out, the functions of factor VIII and/or factor IX, which are proteins that perform critical functions for the development of hemophilia, are inhibited, such that the transgenic rabbit is useful for the development of hemophilia treatments.

公开(公告)号：US20140274918A1

公开(公告)日：2014-09-18

申请号：US13845466

申请日：2013-03-18

Applicant: GREEN CROSS CORPORATION

Inventor： Soongyu CHOI ,  Jae Eun KIM ,  Kwang-Seop SONG ,  Suk Ho LEE ,  Kisoo PARK ,  Hee Jeong SEO ,  Min Ju KIM ,  Eun-Jung PARK ,  So Ok PARK ,  Younggyu KONG ,  Hyunku KANG ,  Ickhawn SON ,  Myung Eun JUNG ,  Man-Young CHA ,  Hyun Jung KIM ,  Jun Sung LEE ,  Mi-Soon KIM ,  Min Woo LEE ,  Kinam LEE

IPC: C07D309/10 ,  C07D409/04 ,  C07D409/14 ,  C07D407/04

CPC classification number: C07D309/10 ,  C07D407/04 ,  C07D409/04 ,  C07D409/14

Abstract: The present invention relates to a method for dual inhibition of sodium-dependent glucose cotransporter 1 (SGLT1) and sodium-dependent glucose cotransporter 2 (SGLT2) present in the intestine and kidney by using the compound of formula I or a pharmaceutically acceptable salt or a prodrug thereof: wherein ring A, ring B, X and Y have the same meanings as defined in the specification.

Abstract translation: 本发明涉及通过使用式I化合物或其药学上可接受的盐或其药学上可接受的盐或其药学上可接受的盐或其药学上可接受的盐或其盐 其前药：其中环A，环B，X和Y具有与说明书中定义相同的含义。

公开(公告)号：US20150152075A1

公开(公告)日：2015-06-04

申请号：US14593071

申请日：2015-01-09

Applicant: GREEN CROSS CORPORATION

Inventor： Soongyu CHOI ,  Kwang-Seop SONG ,  Suk Ho LEE ,  Min Ju KIM ,  Hee Jeong SEO ,  Eun-Jung PARK ,  Younggyu KONG ,  So Ok PARK ,  Hyunku KANG ,  Myung Eun JUNG ,  Kinam LEE ,  Hyun Jung KIM ,  Jun Sung LEE ,  Min Woo LEE ,  Mi-Soon KIM ,  Dong Ho HONG ,  Misuk KANG

IPC: C07D309/10 ,  C07D405/10 ,  C07D407/10 ,  C07D409/10 ,  C07D407/14 ,  C07D413/14 ,  C07D413/10 ,  C07D411/10 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D407/04 ,  C07D409/04

CPC classification number: C07D309/10 ,  C07D405/10 ,  C07D405/14 ,  C07D407/04 ,  C07D407/10 ,  C07D407/14 ,  C07D409/04 ,  C07D409/10 ,  C07D409/14 ,  C07D411/10 ,  C07D413/04 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14

Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.

Abstract translation: 公开了具有对钠依赖性葡萄糖转运蛋白2（SGLT2）具有抑制活性的二苯基甲烷部分的化合物存在于肠和肾中。 公开了包含该化合物作为活性成分的药物组合物，其可用于预防或治疗代谢紊乱，特别是糖尿病。 提供了制备该化合物的方法，以及通过使用该化合物预防或治疗代谢紊乱，特别是糖尿病的方法。